CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk

CCL22突变通过扰乱微环境相互作用驱动自然杀伤细胞淋巴增殖性疾病。

阅读:4
作者:Constance Baer # ,Shunsuke Kimura # ,Mitra S Rana ,Andrew B Kleist ,Tim Flerlage ,David J Feith ,Peter Chockley ,Wencke Walter ,Manja Meggendorfer ,Thomas L Olson ,HeeJin Cheon ,Kristine C Olson ,Aakrosh Ratan ,Martha-Lena Mueller ,James M Foran ,Laura J Janke ,Chunxu Qu ,Shaina N Porter ,Shondra M Pruett-Miller ,Ravi C Kalathur ,Claudia Haferlach ,Wolfgang Kern ,Elisabeth Paietta ,Paul G Thomas ,M Madan Babu ,Thomas P Loughran Jr ,Ilaria Iacobucci ,Torsten Haferlach ,Charles G Mullighan

Abstract

Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) is characterized by clonal expansion of natural killer (NK) cells where the underlying genetic mechanisms are incompletely understood. In the present study, we report somatic mutations in the chemokine gene CCL22 as the hallmark of a distinct subset of CLPD-NK. CCL22 mutations were enriched at highly conserved residues, mutually exclusive of STAT3 mutations and associated with gene expression programs that resembled normal CD16dim/CD56bright NK cells. Mechanistically, the mutations resulted in ligand-biased chemokine receptor signaling, with decreased internalization of the G-protein-coupled receptor (GPCR) for CCL22, CCR4, via impaired β-arrestin recruitment. This resulted in increased cell chemotaxis in vitro, bidirectional crosstalk with the hematopoietic microenvironment and enhanced NK cell proliferation in vivo in transgenic human IL-15 mice. Somatic CCL22 mutations illustrate a unique mechanism of tumor formation in which gain-of-function chemokine mutations promote tumorigenesis by biased GPCR signaling and dysregulation of microenvironmental crosstalk.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。